137 B-cells during preclinical phase of rheumatoid arthritis References 1 de Brito Rocha S, Baldo DC, Andrade LEC. 2019; Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis. Adv Rheumatol. 59(1):2. 2 Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. 2004; Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 350(25):2572–81. 3 Nielen MMJ, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MHMT, Habibuw MR, Vandenbroucke JP, Dijkmans B a C. 2004; Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 50(2):380–6. 4 de Hair MJH, van de Sande MGH, Ramwadhdoebe TH, Hansson M, Landewé R, van der Leij C, Maas M, Serre G, van Schaardenburg D, Klareskog L, Gerlag DM, van Baarsen LGM, Tak PP. 2014; Features of the synovium of individuals at risk of developing rheumatoid arthritis implications for understanding preclinical rheumatoid arthritis: Implications for understanding preclinical rheumatoid arthritis. Arthritis Rheumatol. 66(3):513–22. 5 van de Sande MGH, de Hair MJH, van der Leij C, Klarenbeek PL, Bos WH, Smith MD, Maas M, de Vries N, van Schaardenburg D, Dijkmans BAC, Gerlag DM, Tak PP. 2011; Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis. 70(5):772–7. 6 Bos WH, Wolbink GJ, Boers M, Tijhuis GJ, de Vries N, van der Horst-Bruinsma IE, Tak PP, van de Stadt RJ, van der Laken CJ, Dijkmans B a C, van Schaardenburg D. 2010; Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis. 69(3):490–4. 7 Gerlag DM, Safy M, Maijer KI, Tang MW, Tas SW, Starmans-Kool MJF, van Tubergen A, Janssen M, de Hair M, Hansson M, de Vries N, Zwinderman AH, Tak PP. 2019; Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Ann Rheum Dis. 78(2):179–85. 8 Pollastro S, Klarenbeek PL, Doorenspleet ME, van Schaik BDC, Esveldt REE, Thurlings RM, Boumans MJH, Gerlag DM, Tak PP, Vos K, Baas F, van Kampen AHC, de Vries N. 2019; Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire. Ann Rheum Dis. 78(10):1339–45. 9 Zhang J, Kobert K, Flouri T, Stamatakis A. 2014; PEAR: a fast and accurate Illumina Paired-End reAd mergeR. Bioinformatics. 30(5):614–20. 10 Giudicelli V, Chaume D, Lefranc M-P. 2005; IMGT/GENE-DB: a comprehensive database for human and mouse immunoglobulin and T cell receptor genes. Nucleic Acids Res. 33(Database issue):D256-61. 11 R Core Team. 2021. A language and environment for statistical computing. Vienna, Austria; 12 RStudio Team. MA2020, 2020. RStudio: Integrated Development for R. . Boston; 13 Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JCW. 2006; Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 54(2):613–20. 14 Roll P, Palanichamy A, Kneitz C, Dorner T, Tony H-P. 2006; Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 54(8):2377–86. 6
RkJQdWJsaXNoZXIy MTk4NDMw